Stockreport

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics, Inc.  (RNAZ) 
PDF Patients currently remain on study for continued treatment with TTX-MC138  No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleot [Read more]